Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
AssigneeThe Regents of the University of California
InventorsRobert E. Reiter, Zev Wainberg
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
Claims42
A hybridoma cell line deposited as ATCC Accession No. PTA-9387.
A hybridoma cell line deposited as ATCC Accession No. PTA-9388.
An antibody or fragment thereof capable of binding to domains 1-3 of N-cadherin, the same antigenic determinant of N-cadherin, in vivo or in vitro, as does the monoclonal antibody produced by the hybridoma cell line deposited at the American Type Culture Collection having ATCC Accession No. PTA-9387.
An antibody or fragment thereof capable of binding to domain 4 of N-cadherin, the same antigenic determinant of N-cadherin, in vivo or in vitro, as does the monoclonal antibody produced by the hybridoma cell line deposited at the American Type Culture Collection having ATCC Accession No. PTA-9388.
Dependencies are inferred from the claim text.